New Analyses Reinforce Hemodynamic Benefits of Medtronic Evolut(TM) TAVR Platform in Intermediate Risk Aortic Stenosis Patients | Traderszone

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 31 October, 2017 by The TZ Newswire Staff

New Analyses Reinforce Hemodynamic Benefits of Medtronic Evolut(TM) TAVR Platform in Intermediate Risk Aortic Stenosis Patients

Presented at TCT, Evolut TAVR Platform Showcases Positive Clinical Outcomes in Patients Wanting to Return to More Active Lives

See also
- Next Article Breaking: Bitcoin Futures to Be Launched by CME Group Within Two Months
- Previous Article Online Low-Price Leader? Amazon
Editorial Calender

October 2017

M T W T F S S

1

2 3 4 5 6 7 8

9 10 11 12 13 14 15

16 17 18 19 20 21 22

23 24 25 26 27 28 29

30 31

« Sep Nov »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar